Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

berotralstat

ORLADEYO

berotralstat (ORLADEYO) is a plasma kallikrein inhibitor. Associated with Biocryst.

EMA: approved Blood and blood forming organs (B06) B06AC
Patents linked 17
Pipeline programs 3
News articles 2
Drug details — berotralstat
Class
Blood and blood forming organs (B06)
Route
—
Patents
17
Programs
3
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

berotralstat (ORLADEYO) is a plasma kallikrein inhibitor. Associated with Biocryst.

Key facts

INN berotralstat
Brand ORLADEYO
Mechanism Plasma kallikrein inhibitor
Therapeutic class Blood and blood forming organs (B06)
ATC code B06AC
Originator Biocryst

Mechanism of action

Plasma kallikrein inhibitor

Approval history

Authority Status Date
EMA approved —

Recent coverage

View all news
BioCryst’s New ORLADEYO Data Adds Real-World HAE Evidence
High impact NewsHAEJun 13, 2026

BioCryst’s New ORLADEYO Data Adds Real-World HAE Evidence

HAE · 6 min

BioCryst Pharmaceuticals is presenting new clinical data and real-world evidence for ORLADEYO (berotralstat) in hereditary angioedema. The update matters because it expands the evidence base around an FDA-approved oral prophylactic option for adults and pediatric patients 2 years and older.

Dr. Elena Rossi
BioCryst Presents New HAE Data for ORLADEYO® and Navenibart at EAACI 2026
High impact AnalysisHAEJun 2, 2026

BioCryst Presents New HAE Data for ORLADEYO® and Navenibart at EAACI 2026

HAE · 8 min

BioCryst Pharmaceuticals will present new hereditary angioedema (HAE) data for its oral therapy ORLADEYO® (berotralstat) and its investigational therapy navenibart at the 2026 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting. This presentation highlights BioCryst's ongoing commitment to advancing HAE treatment and understanding.

Dr. Elena Rossi

Pipeline programs

Search pipeline Sponsor programs
  1. BCX7353-304 Phase 3 · Anaxis Pharma · Hereditary Angioedema (HAE)
  2. berotralstat Phase 3 · Biocryst · Hereditary Angioedema
  3. BCX7353-312 Approved · Anaxis Pharma · Hereditary Angioedema

Related & competitor drugs

Browse all drugs
  1. apixaban Blood and blood forming organs (B01)
  2. bivalirudin Blood and blood forming organs (B01)
  3. c1 inhibitor (human) Blood and blood forming organs (B06)
  4. clopidogrel Blood and blood forming organs (B01)
  5. dabigatran etexilate Blood and blood forming organs (B01)
  6. eltrombopag Blood and blood forming organs (B02)

Related patents

Browse patents Biocryst patent hub

  1. US 11559515

    Indole compounds and analogues thereof

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11173159

    Methods and compositions for inhibition of polymerase

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10849883

    Benzopyrazole compounds and analogues thereof

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10420769

    Methods and compositions for inhibition of polymerase

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10022375

    Methods and compositions for inhibition of polymerase

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9580428

    Compositions and methods for inhibiting viral polymerase

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9492452

    Methods and compositions for inhibition of polymerase

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8163703

    Hepatitis C therapies

    Expires Mon Apr 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8133870

    Therapeutic furopyrimidines and thienopyrimidines

    Expires Mon Mar 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7514410

    Hepatitis C therapies

    Expires Mon Apr 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7429571

    Therapeutic furopyrimidines and thienopyrimidines

    Expires Mon Sep 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7045535

    Compounds useful for inhibiting paramyxovirus neuraminidase

    Expires Mon May 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  13. US 6835326

    Fluorescent ink compositions comprising functionalized fluorescent nanocrystals

    Expires Mon Dec 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  14. US 6680211

    Fluorescent nanocrystal-embedded microspheres for fluorescence analysis

    Expires Mon Jan 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  15. US 6576155

    Fluorescent ink compositions comprising functionalized fluorescent nanocrystals

    Expires Mon Jun 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  16. US 6458799

    Deazaguanine analog, preparation thereof and use thereof

    Expires Mon Sep 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  17. US 6268350

    Polynucleotides for inhibiting metastasis and tumor cell growth

    Expires Mon Jul 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is berotralstat?

berotralstat (ORLADEYO) is a plasma kallikrein inhibitor. Associated with Biocryst.

What is the brand name for berotralstat?

ORLADEYO is a marketed brand name for berotralstat. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.